Loading stock data…
$17.07-0.54 (-3.07%)
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Bicara Therapeutics Inc. in the Healthcare sector is trading at $17.07 with a market capitalization of $1.5B. Wall Street consensus targets $35.67 (12 analysts), implying a +108.9% move over the next 12 months. The stock is currently near its 52-week low of $13.70, remaining 20.0% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$59.95M↑ | -$60.24M↓ | -$41.12M↓ | -$40.68M↓ | -$32.02M |
| Net Income | -$55.44M↑ | -$56.21M↓ | -$37.39M↓ | -$36.33M↓ | -$27.39M |
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal g...